Fate Therapeutics Initiates First Patient Dose in Phase 2 Trial of FT819 for Lupus Nephritis
Clinical Initiation and Design
Fate Therapeutics (FATE) completed the first patient dose in the RECLAIM-LN trial in August 2026. NCT07570862 is a potential registration-enabling, single-arm, open-label Phase 2 trial enrolling 53 patients with moderate to severe Class 3 or 4 lupus nephritis who are refractory to at least two existing immunosuppressive therapies. Patients will receive a single dose of 900 million FT819 cells following fludarabine pre-conditioning, with complete renal response (CRR) at 26 weeks as the primary endpoint. Enrollment is expected to be completed by the first half of 2028, with follow-up continuing for 24 months post-dosing and long-term safety monitoring for up to 15 years.
Drug and Platform Differentiation
FT819 is a CD19-targeting chimeric antigen receptor T-cell (CAR-T) candidate developed under a code name without a brand or international non-proprietary name. It is manufactured in allogeneic off-the-shelf format from induced pluripotent stem cells (iPSC), offering faster supply and greater product consistency compared to autologous CAR-T, which requires patient-specific cell collection and manufacturing. The fact that the first patient was treated and discharged on the same day in an outpatient setting could serve as an operational benchmark for potentially shifting the cost structure of inpatient cell therapy. However, as a single-arm trial, the magnitude and durability of CRR, along with infection rates, cytokine release syndrome (CRS), and neurotoxicity, must be interpreted in the context of existing treatment outcomes.
Clinical Rationale and Regulatory Pathway
In the preceding Phase 1 trial NCT06308978, as of April 2026, all three patients in the no-pretreatment dose cohort achieved SRI-4, with two reaching lupus low disease activity state (LLDAS). This supports the development rationale that CD19-positive B-cell depletion and immune reconstitution can suppress renal inflammation for extended periods. However, with a sample size of only three patients, the reproducibility of results in the Phase 2 trial is critical. FT819 has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and is participating in the FDA CMC Development and Readiness Pilot Program to accelerate manufacturing and regulatory discussions. It has not yet entered the approval review or advisory committee (AdComm) stages, and the results of RECLAIM-LN will determine the subsequent regulatory pathway.
Market and Competitive Landscape
The lupus nephritis market is estimated at $2.6 billion in the U.S., EU4, U.K., and Japan combined in 2025. Current standard of care includes corticosteroids and mycophenolate or cyclophosphamide. GSK's Benlysta (belimumab), a BAFF inhibitor, was approved by the FDA in December 2020, and Aurinia Pharmaceuticals' Lupkynis (voclosporin), a calcineurin inhibitor, received FDA approval on January 22, 2021. In the cell therapy space, Novartis (NVS) is conducting a Phase 2 trial of its CD19 CAR-T, rapcabtagene autoleucel, in 179 patients, and Kyverna Therapeutics (KYTX) is also conducting a trial with its autologous CD19 CAR-T, KYV-101. The investment value of FT819 hinges on whether its off-the-shelf supply and lower pre-conditioning intensity compromise clinical efficacy compared to these autologous CAR-T candidates.
RECLAIM-LN is a Phase 2 trial of 53 patients designed as a potential registration-enabling study. If the 26-week CRR is reproducible, it could serve as a key value inflection point for Fate Therapeutics (FATE), validating its iPSC-based off-the-shelf platform. In the short term, enrollment speed, outpatient same-day discharge reproducibility, and rates of CRS, neurotoxicity, and infection will determine clinical execution and cost competitiveness. In the medium to long term, the key question is whether a single-cell therapy can replace the current standard of care, which is based on repeated dosing of Benlysta and Lupkynis, in the $2.6 billion 2025 market across the seven major countries. Novartis (NVS)'s Phase 2 trial of rapcabtagene autoleucel in 179 patients and Kyverna Therapeutics (KYTX)'s KYV-101 are raising the competitive bar, so FT819 will need not only allogeneic manufacturing advantages but also clinical superiority in CRR durability and safety. RMAT designation and participation in the FDA CMC Pilot Program are factors that can accelerate regulatory discussions, but the single-arm design and limited prior patient data constrain comparability and commercial confidence, making a Watchlist rating appropriate.
Source: ClinicalTrials.gov (api_ct)